Physician profile
Anar A Modi
NPI 1972858785
$884.68
in general payments reported to CMS, 2019-2025
17 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $65.25 · 2021: $34.98 · 2022: $63.05 · 2023: $97.86 · 2024: $156 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $202.03 | 2019-2023 | Verquvo |
| Lilly USA, LLC | $137.62 | 2019-2021 | |
| Corcept Therapeutics | $105.80 | 2023-2025 | Korlym |
| Medtronic, INC. | $101.14 | 2024-2025 | Intellis Adaptivestim, Minimed 780g |
| Abbott Laboratories | $45.46 | 2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $43.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $39.59 | 2019 | |
| Insulet Corporation | $28.85 | 2019-2024 | Omnipod |
| Novartis Pharmaceuticals Corporation | $25.78 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.27 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $23.14 | 2020 | |
| Amneal Pharmaceuticals LLC | $22.38 | 2024 | Unithroid |
| Medtronic Minimed, INC. | $21.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.58 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $17.29 | 2024 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.05 | 2024 | |
| Alexion Pharmaceuticals, INC. | $12.85 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anar Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.